HeartSciences (NASDAQ:HSCS) Trading 11.6% Higher – Still a Buy?

HeartSciences Inc. (NASDAQ:HSCS)’s share price was up 11.6% during mid-day trading on Friday . The company traded as high as $2.87 and last traded at $2.80. Approximately 145,570 shares were traded during trading, an increase of 78% from the average daily volume of 81,638 shares. The stock had previously closed at $2.51.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Trading Up 11.6%

The company has a market cap of $10.92 million, a price-to-earnings ratio of -0.71 and a beta of 1.79. The stock has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $2.35.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings data on Thursday, July 23rd. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). As a group, research analysts expect that HeartSciences Inc. will post -3.04 EPS for the current fiscal year.

Institutional Trading of HeartSciences

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC acquired a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.